^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ropidoxuridine (IPdR)

    i
    Other names: IPdR
    Associations

    News

    Trials
    Company:
    National Cancer Institute, Shuttle Pharma
    Drug class:
    DNA inhibitor
    Related drugs:
    Associations

    News

    Trials
    1m
    S22-11168: Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter (clinicaltrials.gov)
    P2, N=30, Terminated, Shuttle Pharmaceuticals, Inc. | N=54 --> 30 | Trial completion date: Feb 2027 --> Dec 2025 | Recruiting --> Terminated | Trial primary completion date: Aug 2026 --> Dec 2025; Terminated due to the sponsor's decision.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    ropidoxuridine (IPdR)
    3ms
    Ropidoxuridine and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases (clinicaltrials.gov)
    P1, N=11, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2025 --> Oct 2026
    Trial completion date
    |
    CD4 (CD4 Molecule)
    |
    ropidoxuridine (IPdR)
    11ms
    Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy (clinicaltrials.gov)
    P1, N=19, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2025 --> Mar 2026
    Trial completion date
    |
    CD4 (CD4 Molecule)
    |
    ropidoxuridine (IPdR)
    over1year
    Ropidoxuridine and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases (clinicaltrials.gov)
    P1, N=11, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2024 --> Oct 2025
    Trial completion date
    |
    CD4 (CD4 Molecule)
    |
    ropidoxuridine (IPdR)
    over1year
    S22-11168: Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter (clinicaltrials.gov)
    P2, N=54, Recruiting, Shuttle Pharmaceuticals, Inc. | Not yet recruiting --> Recruiting | Initiation date: Jun 2024 --> Sep 2024
    Enrollment open • Trial initiation date
    |
    ropidoxuridine (IPdR)
    almost2years
    Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter (clinicaltrials.gov)
    P2, N=54, Not yet recruiting, Shuttle Pharmaceuticals, Inc.
    New P2 trial
    |
    ropidoxuridine (IPdR)
    almost2years
    Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy (clinicaltrials.gov)
    P1, N=19, Active, not recruiting, National Cancer Institute (NCI)
    Trial completion date • Metastases
    |
    CD4 (CD4 Molecule)
    |
    ropidoxuridine (IPdR)
    almost2years
    Ropidoxuridine and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases (clinicaltrials.gov)
    P1, N=11, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2024 --> Sep 2024
    Trial completion date
    |
    CD4 (CD4 Molecule)
    |
    ropidoxuridine (IPdR)
    over2years
    A case report of typhlitis during novel use of ropidoxuridine-capecitabine-radiotherapy for treatment-naïve rectal cancer. (PubMed, Cancer Chemother Pharmacol)
    We believe this case report demonstrates the decision-making process for terminating a phase I accelerated titration designed clinical trial. The report also presents the rare complication of sigmoid typhlitis as a treatment-attributed adverse event. In this case, a ropidoxuridine-capecitabine combination was used as an investigational radiosensitizing treatment now with a narrower future clinical development pathway.
    Journal
    |
    5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • ropidoxuridine (IPdR)
    almost3years
    Ropidoxuridine and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases (clinicaltrials.gov)
    P1, N=11, Active, not recruiting, National Cancer Institute (NCI) | N=47 --> 11 | Trial primary completion date: Dec 2023 --> Aug 2022
    Enrollment change • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    ropidoxuridine (IPdR)
    3years
    Testing the Addition of a Radiation Sensitizing Drug, IPdR, to the Usual Chemotherapy Treatment (Capecitabine) During Radiation Therapy for Rectal Cancer (clinicaltrials.gov)
    P1, N=1, Terminated, National Cancer Institute (NCI) | N=30 --> 1 | Trial completion date: May 2023 --> Jan 2023 | Recruiting --> Terminated | Trial primary completion date: May 2023 --> Jan 2023; Inadequate accrual rate
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Combination therapy
    |
    CD4 (CD4 Molecule)
    |
    capecitabine • ropidoxuridine (IPdR)
    3years
    Ropidoxuridine and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases (clinicaltrials.gov)
    P1, N=47, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023
    Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    ropidoxuridine (IPdR)